Collaborate 2 Cure
November 10, 2016

Engineering Regulatory T Cells for the Treatment of Graft-Versus-Host Disease

Speaker: Tom Yankee, PharmD, PhD

Tom Yankee, PharmD, PhD is an Associate Professor of Microbiology, Molecular Genetics, and Immunology at the University of Kansas Medical Center.  He also holds an appointment in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center.  He also serves as the Scientific Director of the Flow Cytometry Core Laboratory.  His research interests focus on applying an understanding of T cell biology to the field of immunotherapy.  He has designed a novel chimeric antigen receptor platform for the treatment of cancer and is using innovative approaches to the suppression immune responses for graft-versus-host-disease.  Dr. Yankee earned his PharmD degree from the University of Illinois at Chicago and his PhD from the Department of Medicinal Chemistry and Molecular Pharmacology at Purdue University.  He then went to the University of Washington in Seattle and joined the Department of Immunology as a post-doctoral fellow.

Immunotherapy of Osteosarcoma


Pediatric and canine osteosarcoma are remarkably similar, both molecularly and clinically. Treatment for both humans and dogs consists of removal of the tumor, often by amputation of the affected limb, followed by chemotherapy. Despite exploration of different chemotherapy protocols, outcomes have remained consistent for the last 20 years. However, osteosarcoma has long been known to be an immune responsive tumor and studies of immunotherapies in the past have provided leads toward improved treatment. Most recently, a study in canine osteosarcoma using AT-014, a modified live Listeria monocytogenes targeting HER2/neu, has suggested that this approach holds promise for substantially extending survival. Eighteen dogs diagnosed with osteosarcoma were treated with AT-014 following amputation and chemotherapy. Median overall survival of treated dogs was 956 days. A historical control group with similar demographics to the treated dogs had a median overall survival time of 423 days. Adverse events associated with AT-014 were limited to lethargy, fever, and vomiting, and resolved with symptomatic treatment. This construct is currently being developed by Advaxis for use in humans with HER2/neu+ tumors and by Aratana Therapeutics as an aid in the treatment of dogs with osteosarcoma.

Speaker: Laura Simon Treml, VMD, PhD

Dr. Treml is the Senior Director of Research and Development for Immunotherapeutics at Aratana Therapeutics where she leads the development of products related to oncology and immunotherapy, as well as evaluates potential in-licensing opportunities. Prior to joining Aratana, Dr. Treml led the Companion Animal Efficacy group at Bayer Animal Health, where she conducted clinical studies demonstrating the safety and efficacy of pharmaceuticals used in dogs, cats, and other pets. Dr. Treml has also served as Medical Director of a multi-doctor corporate practice and practiced clinical medicine for over ten years. Dr. Treml received her veterinary medical degree and her PhD in Immunology from the University of Pennsylvania, and her BS from the College of William and Mary in Virginia.


Kauffman Foundation Conference Center
Brookside Room
4801 Rockhill Rd, Kansas City, MO 64110

Or join virtually via “Zoom”